Cargando…
Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries
In May 2012, the World Health Assembly declared the completion of poliovirus eradication a programmatic emergency for global public health and called for a comprehensive polio endgame strategy. The Polio Eradication and Endgame Strategic Plan 2013-2018 was developed in response to this call and dema...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853552/ https://www.ncbi.nlm.nih.gov/pubmed/28838169 http://dx.doi.org/10.1093/infdis/jiw573 |
_version_ | 1783306774619619328 |
---|---|
author | Blankenhorn, Anne-Line Cernuschi, Tania Zaffran, Michel J. |
author_facet | Blankenhorn, Anne-Line Cernuschi, Tania Zaffran, Michel J. |
author_sort | Blankenhorn, Anne-Line |
collection | PubMed |
description | In May 2012, the World Health Assembly declared the completion of poliovirus eradication a programmatic emergency for global public health and called for a comprehensive polio endgame strategy. The Polio Eradication and Endgame Strategic Plan 2013-2018 was developed in response to this call and demands that all countries using Oral Polio Vaccine (OPV) only introduce at least 1 dose of Inactivated Polio Vaccine (IPV) into routine immunization schedules by the end of 2015. In November 2013, the Board of Gavi (the Vaccine Alliance) approved the provision of support for IPV introduction in the 72 Gavi-eligible countries. Following analytical work and stakeholder consultations, the IPV Immunization Systems Management Group (IMG) presented a proposal to provide exceptional financial support for IPV introduction to additional OPV-only using countries not eligible for Gavi support and that would otherwise not be able to mobilize the necessary financial resources within the Polio Eradication and Endgame Strategic Plan timelines. In June 2014, the Polio Oversight Board (POB) agreed to make available a maximum envelope of US $45 million toward supporting countries not eligible for Gavi funding. This article describes the design of the funding mechanism that was developed, its implementation and the lessons learned through this process. |
format | Online Article Text |
id | pubmed-5853552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58535522018-07-01 Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries Blankenhorn, Anne-Line Cernuschi, Tania Zaffran, Michel J. J Infect Dis Supplement Article In May 2012, the World Health Assembly declared the completion of poliovirus eradication a programmatic emergency for global public health and called for a comprehensive polio endgame strategy. The Polio Eradication and Endgame Strategic Plan 2013-2018 was developed in response to this call and demands that all countries using Oral Polio Vaccine (OPV) only introduce at least 1 dose of Inactivated Polio Vaccine (IPV) into routine immunization schedules by the end of 2015. In November 2013, the Board of Gavi (the Vaccine Alliance) approved the provision of support for IPV introduction in the 72 Gavi-eligible countries. Following analytical work and stakeholder consultations, the IPV Immunization Systems Management Group (IMG) presented a proposal to provide exceptional financial support for IPV introduction to additional OPV-only using countries not eligible for Gavi support and that would otherwise not be able to mobilize the necessary financial resources within the Polio Eradication and Endgame Strategic Plan timelines. In June 2014, the Polio Oversight Board (POB) agreed to make available a maximum envelope of US $45 million toward supporting countries not eligible for Gavi funding. This article describes the design of the funding mechanism that was developed, its implementation and the lessons learned through this process. Oxford University Press 2017-07-01 2017-06-30 /pmc/articles/PMC5853552/ /pubmed/28838169 http://dx.doi.org/10.1093/infdis/jiw573 Text en © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/3.0/igo/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 IGO (CC BY 3.0 IGO) License (https://creativecommons.org/licenses/by/3.0/igo/) which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Supplement Article Blankenhorn, Anne-Line Cernuschi, Tania Zaffran, Michel J. Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries |
title | Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries |
title_full | Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries |
title_fullStr | Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries |
title_full_unstemmed | Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries |
title_short | Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries |
title_sort | exceptional financial support for introduction of inactivated polio vaccine in middle-income countries |
topic | Supplement Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853552/ https://www.ncbi.nlm.nih.gov/pubmed/28838169 http://dx.doi.org/10.1093/infdis/jiw573 |
work_keys_str_mv | AT blankenhornanneline exceptionalfinancialsupportforintroductionofinactivatedpoliovaccineinmiddleincomecountries AT cernuschitania exceptionalfinancialsupportforintroductionofinactivatedpoliovaccineinmiddleincomecountries AT zaffranmichelj exceptionalfinancialsupportforintroductionofinactivatedpoliovaccineinmiddleincomecountries |